NASDAQ:SGRY - Surgery Partners Stock Price, Price Target & More

Surgery Partners trades on the NASDAQ under the ticker symbol "SGRY."

Surgery Partners declared that its board has authorized a share repurchase program on Saturday, December 16th 2017, which permits the company to buyback $50,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to buy shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company's leadership believes its stock is undervalued.

Surgery Partners (NASDAQ:SGRY) released its quarterly earnings results on Thursday, March, 1st. The company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of $0.08 by $0.11. The company earned $460.30 million during the quarter, compared to the consensus estimate of $438.30 million. Surgery Partners had a negative return on equity of 0.53% and a negative net margin of 4.54%. The company's quarterly revenue was up 50.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.35 EPS. View Surgery Partners' Earnings History.

Surgery Partners is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Surgery Partners.

8 analysts have issued 12-month target prices for Surgery Partners' shares. Their predictions range from $15.00 to $19.00. On average, they expect Surgery Partners' share price to reach $17.6667 in the next year. View Analyst Ratings for Surgery Partners.

Some companies that are related to Surgery Partners include Madrigal Pharmaceuticals (MDGL), NxStage (NXTM), Omnicell Technologies (OMCL), Enanta Pharmaceuticals (ENTA), Abaxis (ABAX), Sangamo Therapeutics (SGMO), Innoviva (INVA), Repligen (RGEN), Acceleron Pharma (XLRN), Xencor (XNCR), Editas Medicine (EDIT), Tivity Health (TVTY), Momenta Pharmaceuticals (MNTA), Sirtex Medical (SRX), Atara Biotherapeutics (ATRA), Mazor Robotics (MZOR), HMS (HMSY) and Radius Health (RDUS).

News headlines about SGRY stock have trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Surgery Partners earned a media sentiment score of 0.06 on Accern's scale. They also gave news headlines about the company an impact score of 45.46 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Surgery Partners' stock is owned by many different of retail and institutional investors. Top institutional shareholders include DOYLE MICHAEL THOMAS (6.10%) and DOYLE MICHAEL THOMAS (6.10%). Company insiders that own Surgery Partners stock include HIG Surgery Centers, Llc and Jennifer Baldock. View Institutional Ownership Trends for Surgery Partners.

Shares of SGRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SGRY stock can currently be purchased for approximately $17.55.

Surgery Partners has a market capitalization of $853.14 million and generates $1.34 billion in revenue each year. The company earns $-52,980,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Surgery Partners employs 10,600 workers across the globe.

Surgery Partners' mailing address is 310 Seven Springs Way Suite 500, Brentwood TN, 37027. The company can be reached via phone at 615-234-5900 or via email at [email protected]